More Information »Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. Mutations in LRRK2 are commonly associated with late-onset Parkinson's disease (PD).
Product Name / Activity
|4534||CZC 54252 hydrochloride|
|Potent LRRK2 inhibitor; neuroprotective|
|Potent, selective LRRK2 inhibitor; brain penetrant|
|Potent and selective LRRK2 inhibitor|
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.